| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
3320 Stock Overview
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and Hong Kong.
China Resources Pharmaceutical Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$4.73 |
| 52 Week High | HK$5.58 |
| 52 Week Low | HK$3.18 |
| Beta | 0.38 |
| 1 Month Change | -4.44% |
| 3 Month Change | 5.11% |
| 1 Year Change | 16.79% |
| 3 Year Change | -41.89% |
| 5 Year Change | -50.11% |
| Change since IPO | -47.50% |
Recent News & Updates
China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
China Resources Pharmaceutical Group Limited's ( HKG:3320 ) dividend will be increasing to HK$0.15 on 25th of July...
Shareholder Returns
| 3320 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 5.8% | -2.8% | -0.5% |
| 1Y | 16.8% | -35.7% | -20.6% |
Return vs Industry: 3320 exceeded the Hong Kong Pharmaceuticals industry which returned -35.7% over the past year.
Return vs Market: 3320 exceeded the Hong Kong Market which returned -20.6% over the past year.
Price Volatility
| 3320 volatility | |
|---|---|
| 3320 Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in HK Market | 12.6% |
| 10% least volatile stocks in HK Market | 3.2% |
Stable Share Price: 3320 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 3320's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 65,000 | Xiaosong Bai | https://www.crpharm.com |
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and Hong Kong. The company operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. It offers a range of chemical drugs, Chinese medicines, and biopharmaceutical drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular, alimentary tract, metabolism and endocrine, respiratory, orthopedics, oncology, medical nutrition, gastroenterology, pediatrics, genitourinary system, cough and cold, anti-infection, dermatology, infusion solutions, etc. The company also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies.
China Resources Pharmaceutical Group Limited Fundamentals Summary
| 3320 fundamental statistics | |
|---|---|
| Market Cap | HK$28.65b |
| Earnings (TTM) | HK$3.77b |
| Revenue (TTM) | HK$236.81b |
7.9x
P/E Ratio0.1x
P/S RatioIs 3320 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3320 income statement (TTM) | |
|---|---|
| Revenue | HK$236.81b |
| Cost of Revenue | HK$201.43b |
| Gross Profit | HK$35.38b |
| Other Expenses | HK$31.61b |
| Earnings | HK$3.77b |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Aug 25, 2022
| Earnings per share (EPS) | 0.60 |
| Gross Margin | 14.94% |
| Net Profit Margin | 1.59% |
| Debt/Equity Ratio | 69.9% |
How did 3320 perform over the long term?
See historical performance and comparison